Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial

Next Previous
Trial Profile

A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Lanreotide (Primary)
  • Indications Gastric cancer; Gastro-enteropancreatic neuroendocrine tumour; Gastrointestinal cancer; Lung cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Thoracic neoplasms
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LOLA; The LOLA Trial

Most Recent Events

  • 26 Sep 2023 Trial design, published in the BMC Cancer
  • 08 Jun 2021 Trial design presented at the 57th Annual Meeting of the American Society of Clinical Oncology
  • 02 Jul 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top